Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M. S. Kipnes
Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
Related publications
Cost-Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Monotherapy in Elderly Type 2 Diabetes Patients in Thailand
ClinicoEconomics and Outcomes Research
Health Policy
Economics
Econometrics
Finance
Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus
Frontiers in Pharmacology
Pharmacology
Effect of Renal Insufficiency on the Pharmacokinetics of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
A Randomized, Placebo- And Sitagliptin-Controlled Trial of the Safety and Efficacy of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Japanese Patients With Type 2 Diabetes
Diabetes, Obesity and Metabolism
Internal Medicine
Endocrinology
Metabolism
Diabetes
Role of Dipeptidyl Peptidase-4 Inhibitor in the Control of Glycemic State in Type I and Type II Diabetes Mellitus in Rats: A Comparative Study
The Medical Journal of Cairo University
Efficacy of High-Dose Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Glycemic Parameters in Patients With Type 2 Diabetes Estimated With Continuous Glucose Monitoring: A Pilot Study
Integrative Obesity and Diabetes
Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Journal of thee Medical Sciences (Berkala Ilmu Kedokteran)
Incretin Mimetics and Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Type 2 Diabetes
European Endocrinology
Endocrine
Endocrinology
Metabolism
Autonomic Systems
Diabetes
An Overview of the Effect of Sodium Glucose Cotransporter 2 Inhibitor Monotherapy on Glycemic and Other Clinical Laboratory Parameters in Type 2 Diabetes Patients
Therapeutics and Clinical Risk Management
